HK2

Across TCGA pan-cancer cohorts, HK2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HK2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HK2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

LIHC, PRAD, and COAD are the cancer types where HK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	1.000	0.677	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.096	0.829	<.001	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.112	0.544	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HK2–LIHC (DFS)

Open the LIHC breakdown →